What is the MLYS stock price?

Mineralys Therapeutics, Inc. (MLYS) last available close: $17.00, as of 11/4/26. Prices on Cylvex may be delayed.

How many analyst price targets for MLYS were reached?

2 of 5 published price targets for MLYS were reached within 12 months (40% reached); 3 are still open. Counts only — firm names and target values are shown to signed-in members.

How many firms publish price targets or ratings on MLYS?

6 firms have published price targets or ratings on MLYS that Cylvex tracks. Counts only — firm names and target values are shown to signed-in members.

Is this investment advice?

No. Cylvex is an educational and informational platform; nothing on this page is investment, financial or trading advice. Past analyst targets do not predict future results.

NASDAQ

MLYS

Mineralys Therapeutics, Inc.

$16.76CS band Caution

☾After Hours −0.25 (−1.45%)Nov 4, 7:59 PM ET

At close $17.00 · +1.01 (+6.33%)

About MLYS

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Why it moved

Moved with Pharmaceuticals peers: RYTM +21.67% · VRDN +15.49% · XNCR +14.26%

From market data · Not investment advice